Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
| Autor: | Hazem Khamis, Ahmed Elkersh, Tamer Mostafa, Ashraf Reda, Ahmed Shawky Elserafy, Mohammed Selim, Osama Sanad, Atef Elbahry, Elsayed Farag, Ahmed Bendary, Nabil Farag, Morad Beshay |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system MEDLINE 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Ezetimibe law Hyperlipidemia Medicine 030212 general & internal medicine Risk factor Adverse effect Intensive care medicine business.industry medicine.disease PCSK-9 Dyslipidemia lcsh:RC666-701 Commentary Kexin Egypt business medicine.drug |
| Zdroj: | The Egyptian Heart Journal The Egyptian Heart Journal, Vol 72, Iss 1, Pp 1-6 (2020) |
| ISSN: | 2090-911X 1110-2608 |
| Popis: | Background The current expert view of the PCSK9 inhibitors’ use in Egypt is still ambiguous. Main body Hyperlipidemia is an important, if not the most important, risk factor for the occurrence of atherosclerosis worldwide. Egypt is the most populous country in the Middle East and North Africa and has > 15% of the cardiovascular deaths in the region. The burden of dyslipidemia as seen in the recently published CardioRisk project conducted throughout Egypt shows a high prevalence of dyslipidemia as a risk factor that is still reaching up to 71% in female participants. Reaching the targets for LDL lowering, and thus control of hyperlipidemia, is quite often very difficult especially with the update of the last ESC guidelines. With the advent of PCSK9 inhibitors, the control rate of patients, reduction of cardiac major adverse events, and mortality have been improved. However, Egypt is not considered a rich country on the grounds of annual income, and this raises a concern on which patients would benefit from these expensive medications. Revising the randomized control trials, we analyzed the data that would enable us to control LDL in those patients, at risk, to obtain simple clear indications for the use of these rather expensive medications. Conclusion We recommend the use of PCSK9 inhibitors in addition to statins ± ezetimibe in patients with ASCVD, by definition at very high risk; patients with ASCVD at very high risk who do not tolerate appropriate doses of at least three statins; and familial hypercholesterolaemia patients with clinically diagnosed ASCVD, at very high cardiovascular risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink